Important to explore new ADCs. Also critical to understand how ADCs currently perform in our pts. At ASCO24, we will present the largest RW cohort to date of pts receiving T-DXd for MBC, including for HER2-0 MBC & after SG. Collaboration Dana-Farber Yale University. meetings.asco.org/abstracts-pres…

Fun evening supporting breast cancer research at the BCRF hot pink in Boston gala - grateful for BCRF support as we work towards a cure Laura Dominici MD Olga Kantor MD, MS, FACS christinaminami Sara Myers Brigham and Women’s Department of Surgery

Insightful case study on the use of GPT-4 at Dana-Farber just published by Renato Umeton, Ph.D. et al. on NEJM AI. Multiple challenges faced during institutional implementation, many important lessons learned. Read the case study here: ai.nejm.org/doi/full/10.10…

Here we are with Dr Sarah Sammons from Dana-Farber’s Breast Oncology Center

simposiocancerdemama.cl

Dana-Farber’s Breast Oncology Center is leading a trial on the use of #ColdCaps in preventing hair loss with novel #BreastCcancer therapies including sacituzumab, eribulin, or trastuzumab deruxtecan. Contact us for info about the study or visit: dana-farber.org/breast-oncolog…… #ScalpCooling ; PI Elahe Salehi DNP

What a tour de force! Fantastic review of LCIS and invasive lobular carcinoma by Tari King MD #GBCC2024 . Dana-Farber’s Breast Oncology Center Brigham and Women’s Department of Surgery

Fantastic review by Tari King MD on post-neoadj residual calcs with MRI resolution. Cant definitively rule out residual disease in suspicious calcs even with MRI resolution so removal of residual calcs necessary. #GBCC2024 #BCSM Dana-Farber’s Breast Oncology Center Brigham and Women's Hospital

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile. bit.ly/3QmlaID

When Vici Robinson’s breast cancer returned at age 81, she found a program designed for patients like her at Dana-Farber. With her cancer stable, Vici is on the move, doing yoga, and volunteering. blog.dana-farber.org/insight/2024/0…

Our new article is out, led by Olga Martínez-Sáez!

Management of early-stage HER2+ breast cancer and attitudes towards HER2DX in Spain

An online questionnaire was conducted by an independent third-party across 70 medical oncologists highly specialized in breast cancer in Spain…

Happy Administrative Professionals Day! Today is a reminder to acknowledge and celebrate the invaluable contributions of individuals who often work tirelessly behind the scenes. Their professionalism, adaptability, and positive attitude make a significant difference! Thank you 🩵

Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (Dr Sarah Sammons) and Nancy Lin (@nlinmd) from Dana-Farber’s Breast Oncology Center. esmoopen.com/article/S2059-…

Insightful discussion on optimizing post neoadjuvant treatment in patients with early #BreastCancer achieving pathologic complete response in Journal of Clinical Oncology from Carmine Valenza Dario Trapani Sibylle Loibl #StephenChia Harold J. Burstein, MD, PhD, FASCO and G Curigliano MD PhD
Read it here👇
pubmed.ncbi.nlm.nih.gov/38569132/

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and TNBC: TROPION-PanTumor01 Study

🔍85 pts, heavily pretreated

HR+/HER2- and TNBC
ORR➡️27% and 32%
PFS➡️8.3 and 4.8 mo
OS➡️ NR and 13.5 mo

ILD➡️1 pts
No treatment-related deaths

OncoAlert
ascopubs.org/doi/10.1200/JC…

We are thrilled to announce that Nelly has been elected as a member of the prestigious American Academy of Arts and Sciences. Congratulations! We're so very proud of you!@nellage Dana-Farber Dana-FarberNews

Our CA: A Cancer Journal for Clinicians review on Agnostic ADCs among the top cited articles of 2022-2023! acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

New report on the risk of radiation necrosis with concurrent ADCs + brain RT. Incidence of symptomatic radiation necrosis was 27% with concurrent vs. 11% with non-concurrent ADC/RT (p=0.014). Important to temporarily stop the ADC before pursuing brain RT. link.springer.com/article/10.100…

Check out Dana-Farber’s recent Momentum article highlighting the #ETHANtrial , led by Jose Pablo Leone, MD, which is aimed at revolutionizing care for #MaleBreastCancer .
📍The trial is open at sites across the US. #BreastCancerInMen Translational Breast Cancer Research Consortium
More here👇
physicianresources.dana-farber.org/news/breast-ca…

April Issue: Defining the Biology of Estrogen Receptor-Low-Positive #BreastCancer Tessa Higgins Olga Kantor MD, MS, FACS Tari King MD Brigham and Women’s Department of Surgery Harold J. Burstein, MD, PhD, FASCO Sara Tolaney Dana-Farber

rdcu.be/dFeaV